Oxamniquine

Essential medicine status

Section: 6. Anti-infective medicines > 6.1. Anthelminthics > 6.1.3. Antischistosomals and other antitrematode medicines

EMLc | ATC codes: P02BA02

Indication	Schistosomiasis due to Schistosoma mansoni ICD11 code: 1F86.1
INN	Oxamniquine
Medicine type	Chemical agent
List type	Complementary
Additional notes	oxamniquine is listed for use when praziquantel treatment fails.
Formulations	**Oral > Liquid:** 250 mg per 5 mL **Oral > Solid > capsule:** 250 mg
EML status history	First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1997 (TRS 882) Changed in 2005 (TRS 933) Changed in 2007 (TRS 950)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Oxamniquine
DrugBank	Oxamniquine

Summary of evidence and Expert Committee recommendations

Oxamniquine is recognized as second-line treatment for the treatment of schistosomiasis [praziquantel remains the first-line choice for all forms of schistosomiasis]. Noting that there are significant research gaps for medicines for children in this area, the EMLc Subcommittee decided to endorse this product as essential but highlighted the need for adequate studies to determine the effectiveness and safety of it in children.